Role and Redirection of IgE against Cancer
AbstractIgE is a highly elusive antibody class, yet a tremendously powerful elicitor of immune reactions. Despite huge efforts spent on the characterization and understanding of the IgE system many questions remain either unanswered or only marginally addressed. One above all relates to the role of IgE. A common doubt is based on whether IgE mode of action should only be relegated to anti-parasite immunity and allergic manifestations. In search for a hidden role of IgE, reports from several laboratories are described herein in which a natural IgE link to cancer or the experimental redirection of IgE against cancer have been investigated. Epidemiological and investigational studies are trying to elucidate a possible direct intervention of endogenous IgE against cancer, raising thus far no definitive evidence. Conversely, experimental approaches implementing several strategies and engineered IgE formats built up a series of convincing results indicating that cancer might be tackled by the effector functions of this immunoglobulin class. Because of its peculiar immune features, IgE may present a superior anti-tumor performance as compared to IgG. However, extreme care should be taken on how IgE-based anti-tumor approaches should be devised. Overall, IgE appears as a promising resource, likely destined to enrich the anti-cancer arsenal.
Scifeed alert for new publicationsNever miss any articles matching your research from any publisher
- Get alerts for new papers matching your research
- Find out the new papers from selected authors
- Updated daily for 49'000+ journals and 6000+ publishers
- Define your Scifeed now
Nigro, E.A.; Siccardi, A.G.; Vangelista, L. Role and Redirection of IgE against Cancer. Antibodies 2013, 2, 371-391.
Nigro EA, Siccardi AG, Vangelista L. Role and Redirection of IgE against Cancer. Antibodies. 2013; 2(2):371-391.Chicago/Turabian Style
Nigro, Elisa A.; Siccardi, Antonio G.; Vangelista, Luca. 2013. "Role and Redirection of IgE against Cancer." Antibodies 2, no. 2: 371-391.